Tumour characteristics, by sex
| Tumour characteristics | Overall cohort (n=1886) | Females (n=437) | Males (n=1499) | p Value |
|---|---|---|---|---|
| Within Milan (n=1882) | 823 (43.7%) | 225 (51.6%) | 598 (41.4%) | <0.001 |
| Vascular invasion (n=1715) | 191 (11.1%) | 36 (8.8%) | 155 (11.9%) | 0.08 |
| BCLC (n=1004) | <0.001 | |||
| Class A | 455 (45.3%) | 137 (56.2%) | 318 (41.8%) | |
| Class B | 248 (24.7%) | 42 (17.2%) | 206 (27.1%) | |
| Class C/D | 301 (29.9%) | 65 (26.8%) | 236 (31.1%) | |
| Maximum tumour diameter (n=1767) | 3.7 (0.38–21.1) | 3.2 (0.6–20.1) | 3.8 (0.38–21.1) | 0.001 |
| Tumour ≥5 cm (n=1886) | 709 (37.6%) | 132 (30.2%) | 577 (39.8%) | 0.001 |
| Unifocal (n=1823) | 991 (54.4%) | 241 (56.6%) | 750 (53.7%) | 0.32 |
| Number of tumours (n=1823) | 0.040 | |||
| 1–2 | 1342 (73.6%) | 331 (77.5%) | 1011 (72.4%) | |
| ≥3 | 481 (26.4%) | 96 (22.5%) | 385 (27.6%) | |
| Lobar involvement (n=1525) | 0.57 | |||
| Left lobe | 453 (29.7%) | 105 (28.8%) | 348 (30.0%) | |
| Right lobe | 809 (53.1%) | 202 (55.3%) | 607 (52.3%) | |
| Both lobes | 263 (17.3%) | 58 (15.9%) | 205 (17.7%) |
Bolded p values indicate significant difference (p<0.05).
AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging classification.